The Asia Pacific is projected to record the highest growth rate in immuno oncology assays market. Factors such as growing number of CROs in the region, increasing awareness about early detection of cancer, and the shift of manufacturers’ and suppliers’ focus from developed economies to emerging economies, such as India and China are driving the growth of this regional segment.
1 In 2018, Roche collaborated with SQZ Biotech to develop antigen presenting cells-based immune-oncology treatments.
2 In 2018, Illumina launched its TruSight Oncology 500 assay, which is used to identify known and emerging tumor biomarkers.
3 In 2018, Roche acquired Tusk Therapeutics to expand its oncology product portfolio.
4 In 2018, Agilent acquired ACEA Biosciences (US). This acquisition will help both the companies to focus on real-time, live-cell analyzes through their expertise in cellular function and metabolism measurements.
5 In 2016, Thermo Fisher collaborated with Invivoscribe Technologies to develop NGS-based in vitro diagnostic oncology tests.
The market study covers the immuno oncology assays market across various segments. It aims at estimating the market size and the growth potential of this market across different segments, on the basis of product, technology, application, indication, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.
The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall immuno-oncology assays market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, and opportunities.
The market for immuno-oncology assays is expected to reach USD 5.9 billion by 2024 from USD 2.9 billion in 2018, at a CAGR of 12.7%.
Moreover, the study showcases back-to-back parameters like application, improvement, product growth, and diverse structures & key processes. The report highlights the in-depth analysis of various critical parameters such as profit & loss statistics, product value, production capability, production process, and many more.
The Immuno Oncology Assays Market report delivers a perfect solution, which incorporates current market intelligence, future projections for the growth, technology inputs, and future market trends.
The report focuses on key strategic developments, analytical tools, and market feature. The report exhibits a top to the bottom estimate of the Immuno Oncology Assays Market which includes key patterns, key players, market drivers, challenges, arrangement patterns, openings, esteem chain, professional outlines, and future guide.
Key Market Players:
The key players operating in the immuno-oncology assays market are Thermo Fischer Scientific (US), Roche Diagnostics (Switzerland), Agilent Technologies (US), and Illumina (US). A majority of the leading players in the market focus on both organic and inorganic growth strategies such as collaborations, partnerships, acquisitions, and agreements to maintain and enhance their market shares in the immuno-oncology assays market.
Know more about key strategies adopted by industry players: